SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Intrinsic Value
SCHOTT Pharma AG & Co KgaA is a DE-based company operating in Life Sciences Tools & Services industry. [ Read More ]
The intrinsic value of one 1SXP stock under the Base Case scenario is 34.58 EUR. Compared to the current market price of 32 EUR, SCHOTT Pharma AG & Co KgaA is Undervalued by 7%.
Valuation Backtest
SCHOTT Pharma AG & Co KgaA
Run backtest to discover the historical profit from buying and selling 1SXP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
SCHOTT Pharma AG & Co KgaA
| Current Assets | 465.2m |
| Cash & Short-Term Investments | 32m |
| Receivables | 260.2m |
| Other Current Assets | 173.1m |
| Non-Current Assets | 776.1m |
| Long-Term Investments | 78.9m |
| PP&E | 654.1m |
| Intangibles | 29.9m |
| Other Non-Current Assets | 13.2m |
| Current Liabilities | 298.5m |
| Accounts Payable | 77.4m |
| Accrued Liabilities | 40.3m |
| Other Current Liabilities | 180.7m |
| Non-Current Liabilities | 223.6m |
| Long-Term Debt | 68.5m |
| Other Non-Current Liabilities | 155.1m |
Earnings Waterfall
SCHOTT Pharma AG & Co KgaA
|
Revenue
|
1.1B
EUR
|
|
Cost of Revenue
|
-730.6m
EUR
|
|
Gross Profit
|
400.2m
EUR
|
|
Operating Expenses
|
-167.5m
EUR
|
|
Operating Income
|
232.7m
EUR
|
|
Other Expenses
|
-36.4m
EUR
|
|
Net Income
|
196.3m
EUR
|
Free Cash Flow Analysis
SCHOTT Pharma AG & Co KgaA
1SXP Profitability Score
Profitability Due Diligence
SCHOTT Pharma AG & Co KgaA's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
SCHOTT Pharma AG & Co KgaA's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
1SXP Solvency Score
Solvency Due Diligence
SCHOTT Pharma AG & Co KgaA's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
SCHOTT Pharma AG & Co KgaA's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
1SXP Price Targets Summary
SCHOTT Pharma AG & Co KgaA
According to Wall Street analysts, the average 1-year price target for 1SXP is 39.44 EUR with a low forecast of 30.3 EUR and a high forecast of 47.25 EUR.
Shareholder Return
1SXP Price
SCHOTT Pharma AG & Co KgaA
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -23% |
| Market Capitalization | 4.8B EUR |
| Shares Outstanding | 150 614 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SCHOTT Pharma AG & Co KgaA is a DE-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Mainz, Hessen. The company went IPO on 2023-09-28. SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The firm's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one 1SXP stock under the Base Case scenario is 34.58 EUR.
Compared to the current market price of 32 EUR, SCHOTT Pharma AG & Co KgaA is Undervalued by 7%.
You don't have any saved screeners yet
